Scarica l'app Stockscreener
17.03
0.65%
0.11
Dopo l'orario di chiusura:
17.01
-0.02
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Franklin Resources Inc. Trims Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $81.33 - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation - AccessWire
Keros Therapeutics, Inc. (NASDAQ:KROS) Stake Lowered by Y Intercept Hong Kong Ltd - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by State Street Corp - Defense World
(KROS) Investment Analysis and Advice - Stock Traders Daily
Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share - Seeking Alpha
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Keros Therapeutics: Hold Through The Dust - Seeking Alpha
Keros Therapeutics (NASDAQ:KROS) Shares Down 5.7% After Analyst Downgrade - Defense World
Keros Therapeutics (NASDAQ:KROS) Given New $63.00 Price Target at Oppenheimer - Defense World
Keros Therapeutics (NASDAQ:KROS) Trading Down 5.7% After Analyst Downgrade - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Shares Gap Down Following Analyst Downgrade - Defense World
Keros Therapeutics shares price target cut on ceased dosing By Investing.com - Investing.com Canada
Where Keros Therapeutics Stands With Analysts - Benzinga
Keros Therapeutics (NASDAQ:KROS) Shares Gap Down on Analyst Downgrade - MarketBeat
Oppenheimer Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $63.00 - MarketBeat
Guggenheim Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat
HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $47.00 - Defense World
Keros Stock Hits Rock Bottom After Pulmonary Hypertension Trial Halt, But Retail Bets On A Rebound - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Scotiabank Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Keros Therapeutics price target raised to $28 from $11 at Wells Fargo - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Investors to Inquire about Securities Investigation - AccessWire
Jefferies sees limited efficacy but keeps Keros Therapeutics stock at Buy - Investing.com
Blow For Keros’s PAH Candidate As Dreams Of Surpassing Winrevair Fade - Citeline
HC Wainwright Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
William Blair Downgrades Keros Therapeutics (KROS) - MSN
Traders Purchase High Volume of Keros Therapeutics Call Options (NASDAQ:KROS) - Defense World
TD Cowen Downgrades Keros Therapeutics (KROS) - MSN
TD Cowen cuts Keros Therapeutics stock to Hold on trial concerns - Investing.com Canada
Keros Therapeutics stock hits 52-week low at $18.63 By Investing.com - Investing.com South Africa
Keros Therapeutics shares downgraded to neutral by BTIG on clinical trial - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out - AccessWire
Keros stock plunges 73% on drug study halt over safety concerns (update) - MSN
Keros stock wilts as it halts two dosing arms in hypertension study - BioWorld Online
Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial - Reuters
Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead Drug - Yahoo! Voices
Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff (KROS) - Seeking Alpha
Lexington biotech's stock crashes after partial drug trial pause - The Business Journals
Keros Therapeutics stock hits 52-week low at $18.63 - Investing.com
Keros stock plunges 76% on drug study halt over safety concerns - MSN
Keros Therapeutics (NASDAQ:KROS) Downgraded to Hold Rating by TD Cowen - MarketBeat
Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Benzinga
Keros Thera slumps after halting parts of cibotercept trial - The Pharma Letter
Keros Therapeutics (NASDAQ:KROS) Lowered to "Market Perform" Rating by William Blair - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Downgraded by BTIG Research to "Neutral" - MarketBeat
Keros Therapeutics Loses 75% Value In A Single SessionHere's Why - Benzinga
Keros Therapeutics halts dosing of blood pressure treatment after safety review - MSN
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Keros Therapeutics halts dosing in trial after adverse events By Investing.com - Investing.com Nigeria
Keros Therapeutics halts dosing in trial after adverse events - Investing.com
Keros Plunges After Dosing Halted in Lung Drug Trial on Safety - BNN Bloomberg
Keros' stock tanks after halting 2 arms of hypertension trial over fluid buildups around heart - Fierce Biotech
Keros Therapeutics provides update on Phase 2 TROPOS trial - TipRanks
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):